Nona Biosciences: Announces Global License and Option Agreement With AstraZeneca for Monoclonal Antibody to Be Developed Into Novel Tumor Targeted Therapies
Nona Biosciences: Announces Global License and Option Agreement With AstraZeneca for Monoclonal Antibody to Be Developed Into Novel Tumor Targeted Therapies
Nona Biosciences：宣佈與阿斯利康簽訂全球許可和期權協議，將單克隆抗體開發成新的腫瘤靶向療法
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊